克罗恩病中度术后复发的管理:治疗升级的随机对照试验,POMEROL 试验。 (波美侯) (POMEROL)
Study type : A 30 months, multicentre, open-label strategic randomized controlled trial
Population : Chron's Disease (CD) patients with an i2 endoscopic postoperative recurrence in the year following ileocolonic resection (6-12months after ileocolonic resection).
Treatments :
Stratification at inclusion according to prophylactic therapy.
Patients randomized in 2 arms:
- Status quo arm: if the patient received no prophylactic therapy, no treatment will be started; if the patient received a prophylactic therapy, the same will be continued at the same dose.
- Therapy escalation arm: infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards.
Main objective : To evaluate the proportion of CD patients without endoscopic postoperative recurrence (i0-i1) at 12 months in the arm receiving therapy escalation compared to status quo arm in patients having an i2 endoscopic postoperative recurrence 6-12months after ileocolonic anastomosis with restoration of faecal stream.
研究概览
详细说明
Number of patients : 360 patients in approximatively 25 sites in France.
Recruitement period : The trial duration for each patients will be 12 months from radomization (18 to 24 months from screening (ie : post-operatively))
Endpoints:
Primary endpoints: Proportion of patients with an i0-i1 modified Rutgeerts score at 12 months.
Secondary endpoints:
-
Proportion of patients with an i3-i4 modified Rutgeerts score at 12 months
-
Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months
-
Proportion of patients with an i0 modified Rutgeerts score at 12 months
-
PRO2 score at 12 months
-
Clinical postoperative recurrence within 12 months: average daily SF ≥ 3.5 and average daily AP score ≥ 1.5, AND
- increased CRP compared to inclusion, at least + 10 mg/l
- OR increased fecal calprotectin compared to inclusion, at least + 250 μg/g
-
Surgical recurrence within 12 months: need for a new ileocolonic resection
-
Endoscopic dilatation within 12 months: need for a balloon insufflation at the ileocolonic anastomosis during an ileocolonoscopy when a non-passable stenosis was present in patient having obstructive symptoms (CDOS > 4) before endoscopy
-
Time to clinical postoperative recurrence
-
Serious adverse events
-
Quality of life: EQ5D-5L questionnaire
-
Work productivity: Work Productivity and Activity Impairment questionnaire
研究类型
注册 (实际的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
-
Paris、法国、75009
- GETAID
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Crohn's disease diagnosed according usual criteria
- Bowel resection with ileocolonic anastomosis performed removing all inflammatory lesions
- Postoperative endoscopy performed between 6 and 12 months after ileocolonic anastomosis reaching the neoterminal ileum (patients who underwent a two stage surgical procedure are also eligible if the endoscopic evaluation is performed 6-12 months after restoration of the fecal stream)
- Moderate endoscopic postoperative recurrence classified i2 according to the Rutgeerts score at 6-12 months, validated by a blinded central reading
Exclusion Criteria:
- Patients with an ostomy
- Ulcerative colitis or IBD type unclassified
- Ileorectal or ileal pouch-anal anastomosis
- Symptoms defined as average daily SF ≥ 3.5 and average daily AP score ≥ 1.5 having started after a free interval without symptoms of at least one month after surgery
- Patients with obstructive symptoms of CD defined by a CDOS > 4
- Patients exposed to infliximab before index surgery with a primary non-response (no clinical effect after 2 infusions at the discretion of the treating gastroenterologist) or history of infusion reactions to infliximab or history of detectable anti-infliximab antibodies
- Patients treated with biological therapy (except for intraocular injections) or an investigational medical product after index surgery
- Patients having started thiopurines or methotrexate more than 6 weeks after ileocolonic anastomosis with restoration of the fecal stream
- Patients in whom not all inflammatory lesions have been removed at index surgery
- Patients with active perianal Crohn's disease
- Patients with a contraindication to infliximab: cancer in the 5 years prior to inclusion excluding non-melanoma skin cancer, active tuberculosis or untreated latent tuberculosis, moderate or severe heart failure, HIV or HBV infection (serology < 6 months), recent live vaccination (within 4 weeks of baseline)
- Pregnant women
- Patients under legal protection or unable to express their consent.
- Patients not affiliated to a health insurance system.
- Patients deprived of liberty by judiciary or administrative decision or hospitalized without consent or admitted in a sanitary or social institution for another reason than research.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Status quo arm
If the patient received no prophylactic therapy after resection, no treatments will be started. If the patient received a prophylactic therapy after resection, the same will be continued at the same dose. |
Stratification 1 : No treatments Stratification 2 : Immunosuppressors at same dose |
|
实验性的:Therapy escalation arm
Infliximab-CT-P13 will be started with two intravenous infusions of 5 mg per kg bodyweight at week 0 and week 2 and subcutaneous injections of 120 mg every 2 weeks from week 6 onwards. |
Stratification 1: Infliximab-CT-P13 Stratification 2: Infliximab-CT-P13 in combination with immunosuppressors
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of patients with an i0-i1 modified Rutgeerts score at 12 months.
大体时间:Month12
|
Number of patients with an i0-i1 modified Rutgeerts score at 12 months. |
Month12
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of patients with an i3-i4 modified Rutgeerts score at 12 months
大体时间:Month 12
|
Number of patients with an i3-i4 modified Rutgeerts score at 12 months |
Month 12
|
|
Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months
大体时间:Month 12
|
Proportion of patients with an i2b-i3-i4 modified Rutgeerts score at 12 months |
Month 12
|
|
Proportion of patients with an i0 modified Rutgeerts score at 12 months
大体时间:Month 12
|
Proportion of patients with an i0 modified Rutgeerts score at 12 months |
Month 12
|
|
Patient Reporting Outcome score at 12 months.
大体时间:Screening, Baseline, week 2, week 6, Month 4, Month 8, Month 12
|
Patient Reporting Outcome score at 12 months will be assessed for the evaluation of disease activity (clinical remission). |
Screening, Baseline, week 2, week 6, Month 4, Month 8, Month 12
|
|
Clinical postoperative recurrence
大体时间:Baseline, Month 4, Month 8, Month 12
|
Clinical postoperative recurrence within 12 months defined by : Average daily Stool Frequency ≥ 3.5 and average daily Abdominal Pain score ≥ 1.5, AND
Average daily Stool frequency, average daily Abdominal Pain score, CRP and Calprotectin feacal will be combined to report the clinical postoperative recurrence (this outcome is is expressed without units) |
Baseline, Month 4, Month 8, Month 12
|
|
Surgical recurrence within 12 months
大体时间:Baseline, Month 4, Month 8, Month 12
|
Surgical recurrence within 12 months defined by need for a new ileocolonic resection. Proportion of surgical recurrence within 12 months |
Baseline, Month 4, Month 8, Month 12
|
|
Endoscopic dilatation within 12 months
大体时间:Baseline, Month 4, Month 8, Month 12
|
Endoscopic dilatation within 12 months defined by a need for a balloon insufflation at the ileocolonic anastomosis during an ileocolonoscopy when a non-passable stenosis was present in patient having obstructive symptoms (CDOS > 4) before endoscopy Proportion of endoscopic dilatation within 12 months |
Baseline, Month 4, Month 8, Month 12
|
|
Time to clinical postoperative recurrence will be assessed
大体时间:Baseline, Month 4, Month 8, Month 12
|
Time to clinical postoperative recurrence will be assessed |
Baseline, Month 4, Month 8, Month 12
|
|
Serious adverse events
大体时间:Screening, Baseline, Month 4, Month 8, Month 12
|
Occurence of Serious Adverse Events |
Screening, Baseline, Month 4, Month 8, Month 12
|
|
Quality of life: EQ5D-5L questionnaires
大体时间:Baseline, week 2, week 6, Month 4, Month 8, Month 12
|
Quality of life will be assessed with the EQ5D-5L questionnaire |
Baseline, week 2, week 6, Month 4, Month 8, Month 12
|
|
Work productivity and activity impairement questionnaires
大体时间:Baseline, week 2, week 6, Month 4, Month 8, Month 12
|
Work productivity and activity impairement will be assessed with work productivity and activity impairement questionnaires |
Baseline, week 2, week 6, Month 4, Month 8, Month 12
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.